Technology Available for Industry-Academia Collaboration or Technology Licensing. “Opioid Receptor Allosteric Modifier: DBPR116” (2021/1/28)

Title:NHRI technology, “Opioid Receptor Allosteric Modifier: DBPR116” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description:The Technology relates to antagonist-to-agonist allosteric modifiers (AAM) of a mu-opioid receptor (MOR) for treating an opioid receptor-associated condition. In the presence of this unique AAM (DBPR116), MOR could be selective activated…

Continue reading

NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” available for technology licensing (exclusive license), 2020/08/17

Subject NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” (abbreviated as “The Technology”) available for technology licensing (exclusive license). Description The Technology is to use induced stem cell-derived exosomes, instead of stem cells, as regeneration medicine. The invention is a method of inducing stem cells to release exosomes…

Continue reading

Technology Available for Technology Licensing. “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine(Jul 20,2020)

1.Title “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine” (abbreviated as “The Technology”) available for technology licensing. 2.Description: The present invention relates to a method for reducing the addictive andpsychotomimetic side effects of ketamine and enhancing the medical efficacy of ketamine. It is characterized…

Continue reading

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

技術移轉

1. Title: NHRI technology, “A Potential COVID-19 Therapeutic Compound” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: The Technology is a novel compound which, in coronaviral infected cells, targets the RNP complex containing viral RNA and nucleoprotein to block viral replication and activities for anti-coronaviral mechanism….

Continue reading

NHRI technology, “Influenza vaccine production using suspension MDCK (NHRI sMDCK) cells” (abbreviated as “The Technology”) available for technology licensing. (2020/04/15)

技術移轉

Description The licensing technology is about a proprietary Madin-Darby canine kidney cell line (NHRI sMDCK) capable of growing in suspension culture without serum. Further disclosed are culturing methods for growing the NHRI sMDCK cell line and methods for producing a vaccine from the MDCK cell line grown in the chemically…

Continue reading